// App-Quantinova.ai

4261 : Utilization and Costs of Red Blood Cell Transfusions Pre- and Post-Azacitidine in Higher-Risk Myelodysplastic Syndromes

Researchers

Presenter

  • Soojin Seung

Principal Investigators

  • Nicole Mittmann

  • Jeannie Callum

  • Richard A. Wells

  • Tony Kim

  • Rena Buckstein

Medical Centers

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Department of Surgery, University of Toronto, Toronto, ON, Canada

  • Department of Medicine, Division of Clinical Pharmacology, HOPE Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Locations

  • Canada

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Red Blood Cells

Drug/Treatment

  • Vidaza

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved